Navigation Links
Study in Cell by Magen BioSciences Co-Founder David E. Fisher,Identifies New Roles in Skin Cancer Prevention for Key Tumor,Suppressor Protein

logical pigmentation disorders such as vitiligo, melasma, solar lentigos and post-inflammation hyperpigmentation."

About Magen BioSciences

Magen BioSciences is a specialty pharmaceutical company focused on developing proprietary medical therapies for the dermatology market. Magen was co-founded in March 2006 by Richard Aldrich, David Fisher, M.D. Ph.D., Phillip Sharp, Ph.D., David Shaw, Christopher Walsh, Ph.D. and Christoph Westphal, M.D., Ph.D. Investors include Alexandria Real Estate, ARCH Venture Partners, Highland Capital Partners, IDG Ventures, Lux Capital, QVT Financial LP, TVM Capital and Venrock Associates.

Contact

for Magen BioSciences, Inc.
Kathryn Morris, 845-635-9828
Kathryn@kmorrispr.com
www.magenbiosciences.com


'"/>




Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

Post Your Comments:
(Date:11/6/2009)...TICK, Mass., Nov. 6 Bost...unced that it has reached an agreement in principl...d to product advisories issued by its Guidant subs...ales occurred prior to Boston Scientific,s 2006 ac...previously disclosed an investigation by the U.S. ...
(Date:11/6/2009)...N DIEGO, Nov. 6 Ardea Bi...company focused on the development of small-molecu...and human immunodeficiency virus (HIV), today repo...for the third quarter and nine months ended Septem...om/cgi-bin/prnh/20091104/ARDEALOGO ) ,, "Since ...
(Date:11/6/2009)...LANTA, Nov. 6 GeoVax La..."the Company"), an Atlanta-based, biopharmaceutica...aused by HIV-1 (Human Immunodeficiency Virus) and ... quarter 2009 financial results and provided an op...sident and Chief Executive Officer commented, "We ...
Breaking Medicine Technology:Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 2Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 3Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 4Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 5Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 6Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 7Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 8Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 9Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 10Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 11Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 12Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 13Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 14Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 15Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 16Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 17Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 2Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 3Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 4Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 6Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 7Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 8GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 4GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 5GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 6GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 7GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 8Alcon Commences Phase 2 Clinical Trial of NovaBays NVC 422 for Viral Conjunctivitis 4680 1Alcon Commences Phase 2 Clinical Trial of NovaBays NVC 422 for Viral Conjunctivitis 4680 2Alcon Commences Phase 2 Clinical Trial of NovaBays NVC 422 for Viral Conjunctivitis 4680 3Alcon Commences Phase 2 Clinical Trial of NovaBays NVC 422 for Viral Conjunctivitis 4680 4Working Out in the Garden 50717 1On Memory Older Americans Outsmart the English 50713 1On Memory Older Americans Outsmart the English 50713 2
(Date:11/8/2009)...Nov. 8 Pharmaceutical R...r Vice President Ken Johnson released the followin... bill: ,, "We are disappointed, but not surpris...ions of hardworking Americans as well as nearly ha...ives who voted against the bill. ,, "While well...
(Date:11/8/2009)...s House Passage of Health Care Reform Bill ,, ...mprove coverage for all Americans ,, BALTIMORE...ight the United States House of Representatives pa...would strengthen Medicare for seniors and end disc...ions of Americans out of affordable health coverag...
(Date:11/7/2009).... 7 The American Medica...Director of Health at the Family Violence Preventi...ce today at its semi-annual policy-making meeting....ghest honor the AMA House of Delegates bestows on ...com.com/cgi-bin/prnh/20081209/AMALOGO ) ,, "M...
(Date:11/7/2009)...ithful Catholics have a responsibility to vigorous...e status quo." ,, WASHINGTON, Nov. 7 /PRNew...nt Judie Brown released the following statement on... Speaker Nancy Pelosi,s Affordable Health Care for...eserving the status quo for abortion is voted upon...
(Date:11/7/2009)...ssume that all youth will rebel, expert says , ...are more likely to behave badly if their parents e...nts who believe they are simply being realistic mi...ecy," Christy Buchanan, a psychology professor at ... said in a university news release. "Negative expe...
Breaking Medicine News(10 mins):Health News:PhRMA Statement on House Passage of Health Care Reform Bill 2Health News:PhRMA Statement on House Passage of Health Care Reform Bill 3Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:AMA Honors Family Violence Prevention Expert 2Health News:Statement Regarding Cardinal Rigali's Memo Protecting the 'Status Quo' On Life 2Health News:Bad-Behaving Teens May Be Living Up to Expectations 2
...teran nonprofit executive, presided over LiveSTRON...hood injury prevention mission,, WASHINGTON, Apri...ganization dedicated exclusively to child injury,p...scom.com/cgi-bin/prnh/20080410/DC19130-a ), (LOG...
...NTA ANA, Calif., April 10 Integrated,Healthcare H...announced,today it has named Edward S. Gyimah as i...of compliance with government regulation of its,ho...anes-Oxley compliance program. Prior to his employ...
... Researchers at Johns Hopkins have discovered that...l nerve cells with blood pressure controlling prot...ls throughout the body might have the same power o...rowing nerve which way to grow, says David Ginty, ...
...rivative of protein produced by bacteria blocked ...AY, April 10 (HealthDay News) -- A modified versio...imals against the damage caused by the kind of rad... Andrei V. Gudkov, senior vice president for basic...
... Washington, D.C. (April 10, 2008) Carotid arter...tients who are not eligible for surgery, according...England Journal of Medicine. Carotid artery diseas...sults important for the estimated 200,000 American...
...LLAS, April 10 ACCESS PHARMACEUTICALS, INC.,(OTC ...laborators at,prestigious institutes in France and...its lead anticancer compound, ProLindac(TM), at th...esentation entitled "Characterization of predictiv...
Other Medicine News:Health News:Safe Kids Worldwide Names Stoller New President, CEO 2Health News:Safe Kids Worldwide Names Stoller New President, CEO 3Health News:IHHI Announces Chief Compliance Officer Appointment 2Health News:Blood vessels: The pied piper for growing nerve cells 2Health News:New Drug Protects Against Radiation Damage 2Health News:SAPPHIRE trial shows long-term benefit of carotid stenting as alternative to surgery 2Health News:SAPPHIRE trial shows long-term benefit of carotid stenting as alternative to surgery 3Health News:Access Pharmaceuticals to Present New Data on ProLindac(TM) at the AACR Annual Meeting 2008 Conference 2Health News:Access Pharmaceuticals to Present New Data on ProLindac(TM) at the AACR Annual Meeting 2008 Conference 3
Fixed Core Straight Safety Wire Guides - Standard (stainless steel)
Mitty-Pollack Needle Set - Standard
Light Guide Cables - 3.5mm
High Transmission Autoclavable Fiberoptic Light Guide, with 45 angled instrument fitting, snap-on
Medicine Products: